Product hub: High-throughput screening of cyclic peptide libraries for developing drugs to challenging targets
Posted: 28 September 2021 | BMG Labtech GmbH | No comments yet
Professor Christian Heinis explains how peptides could offer the next generation of therapeutics and what is required to screen libraries of cyclic peptides.
Your lab is known for the development of cyclic peptides as drugs. How do they differ from conventional compounds and what are their benefits?
Cyclic peptides have excellent binding properties, allowing them to bind to targets with flat, featureless surfaces for which it can be difficult or impossible to develop ligands based on classical small molecules. Another strength of cyclic peptides is their typically low toxicity due to their high target specificity and because their degradation results in amino acids. Yet another advantage of cyclic peptides is the availability of powerful techniques to develop them, for example, phage display or solid-phase peptide synthesis.
Related content from this organisation
- Product hub: High-throughput screening of cyclic peptide libraries for developing drugs to challenging targets
- Application note: Screening for optimal association and dissociation rates of ligands using a live cell binding assay
- Expert view: Promising methods in kinase screening
- Screening In-Depth Focus 2019
- Under the microscope: Improving hit discovery efficiency at Europe´s leading screening centre
Related topics
Amino acids, Drug Development, High Throughput Screening (HTS), Peptide therapeutics, Small Molecules
Related organisations
BMG Labtech GmbH
